MOMENTA PHARMACEUTICALS INC
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.9M | $138.9M | $109.6M | $89.7M | $52.3M |
| Operating income | −$48.1M | −$49.0M | −$92.6M | −$74.7M | −$84.4M | −$99.4M |
| Net income | — | — | — | — | — | — |
| Total assets | $618.4M | $531.6M | $459.4M | $477.7M | $421.0M | $256.2M |
| Total liabilities | $163.9M | $70.6M | $85.3M | $105.8M | $51.1M | $49.8M |
| Equity | $454.5M | $461.0M | $374.2M | $371.9M | $370.0M | $206.4M |
| EPS (diluted) | $-0.46 | $-0.63 | $-0.46 | $-0.35 | — | — |
| Shares out. | 98.5M | 76.9M | 71.9M | 69.1M | 55.0M | 52.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −1169.2%
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Return on capital (ROCE)
- −9.4%
- Liabilities / assets
- 26.5%
- Debt / equity
- 0.36×
- Book value / share
- $4.61
- Revenue growth (YoY)
- −15.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- 1.53grey zone
- Piotroski F-Score
- 0/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 1 good- Operating losses (negative operating margin)
- Revenue declined year-over-year
- Negative operating cash flow
- Altman Z″ in the grey zone
- Conservative leverage (liabilities < 50% of assets)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Manning Anthony M.Officer — Chief Scientific Officer | Oct 1, 2020 | D | 12,778 | — |
| Kwon YoungOfficer — Chief Financial & Bus. Officer | Oct 1, 2020 | D | 160,633 | — |
| Cieplinska AgnieszkaOfficer — Chief Accounting Officer (PAO) | Oct 1, 2020 | D | 8,136 | — |
| Carvajal AlejandraOfficer — Chief Legal Officer | Oct 1, 2020 | D | 28,795 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventOct 1, 2020
- Entered a material agreement · Director / officer change · Regulation FD disclosureAug 19, 2020
- Results of operationsAug 10, 2020
- Director / officer change · Shareholder voteJun 24, 2020
- Regulation FD disclosureJun 15, 2020
- Results of operationsMay 7, 2020
- Director / officer changeApr 10, 2020
- Other material eventApr 2, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.